Oct. 15, 2012
/PRNewswire/ -- Optimer Pharmaceuticals (NASDAQ: OPTR) today announced that new research findings for
infection (CDI) and DIFICID® (fidaxomicin) tablets will be featured in presentations at IDWeek 2012 occurring October 17-21 in San Diego, CA.
- 692 – "Risk Factors for Recurrent Clostridium difficile Infection (CDI) Hospitalization among Hospitalized Patients with an Initial CDI Episode" – Friday, October 19 from 11:30 a.m. Pacific Time in SDCC 29 ABCD
- 693 – "Length of Stay and Hospital Costs in Patients with Hospital-Origin Clostridium difficile-Associated Diarrhea" – Friday, October 19 from 11:45 a.m. Pacific Time in SDCC 29 ABCD
About Clostridium difficile-associated Diarrhea (CDAD)
- 316 – "Development and Validation of a Recurrent Clostridium difficile (CDI) Risk Prediction Model" – Thursday, October 18 from 12:30 PM to 2:00 p.m. Pacific Time in : Room: SDCC Poster Hall F-H
- 824 – "Comparative Microbiology of Transcription Inhibitors Fidaxomicin and the Rifamycins in Clostridium difficile" – Friday, October 19 from 12:30 PM to 2:00 p.m. Pacific Time in : Room: SDCC Poster Hall F-H
infection (CDI) is a serious illness resulting from infection of the inner lining of the colon by
bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.
-associated diarrhea is the most common symptom of CDI. In recent years,
has surpassed methicillin-resistant
(MRSA) as the leading cause of healthcare-acquired infections in community hospitals. Patients typically develop CDAD from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, possibly allowing
bacteria to flourish.